Pantoprazole pretreatment elevates sensitivity to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo.
Lu ZN, Shi ZY, Dang YF, Cheng YN, Guan YH, Hao ZJ, Tian B, He HW, Guo XL.
Biomed Pharmacother. 2019 Sep 27;120:109478. doi: 10.1016/j.biopha.2019.109478.

The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review.  Abbas MK, Zaidi ARZ, Robert CA, Thiha S, Malik BH.  Cureus. 2019 Sep 4;11(9):e5563. doi: 10.7759/cureus.5563.

Outcomes of Prophylactic Pantoprazole in Adult Intensive Care Unit Patients Receiving Dialysis: Results of a Randomized Trial.  Schefold JC, Krag M, Marker S, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, Keus F, Guttormsen AB, Lange T, Møller MH; the SUP-ICU investigators.  Am J Nephrol. 2019;50(4):312-319. doi: 10.1159/000502732.

Subcutaneous pantoprazole in an elderly, palliative care patient.  Michelon H, Souchu H, Chauvron-Defilippi B, Lecoeur A, Villart M, Denis M.  BMJ Support Palliat Care. 2019 Aug 28. pii: bmjspcare-2019-001916. doi: 10.1136/bmjspcare-2019-001916.

Comparison of the gastric acid inhibition function among lansoprazole, pantoprazole, and their respective stereoisomers in healthy Chinese subjects.  Yu L, Sun LN, Zhang XH, Xu YH, Zhang HW, Shen YW, Xie LJ, Wang MF, Jiao HW, Li YQ, Wang YQ, Liu Y.  Int J Clin Pharmacol Ther. 2019 Nov;57(11):552-560. doi: 10.5414/CP203514.

Pantoprazole in ICU patients at risk for gastrointestinal bleeding-1-year mortality in the SUP-ICU trial.  Marker S, Krag M, Perner A, Wetterslev J, Lange T, Wise MP, Borthwick M, Bendel S, Keus F, Guttormsen AB, Schefold JC, Rasmussen BS, Elkmann T, Bestle M, Arenkiel B, Laake JH, Kamper MK, Lång M, Pawlowicz-Dworzanska MB, Karlsson S, Liisanantti J, Dey N, Knudsen H, Granholm A, Møller MH; SUP-ICU trial investigators.  Acta Anaesthesiol Scand. 2019 Oct;63(9):1184-1190. doi: 10.1111/aas.13436.

Effects of Somatostatin Combined with Pantoprazole on Serum C-Reactive Protein and Intercellular Adhesion Molecule-1 in Severe Acute Pancreatitis.  Liu J, Wang G, Liu Y, Huang L, Xu X, Wang J.  J Coll Physicians Surg Pak. 2019 Jul;29(7):683-684. doi: 10.29271/jcpsp.2019.07.683.

Intragastric pH effect of 20mg of levo-pantoprazole versus 40mg of racemic pantoprazole the first seven days of treatment in patients with gastroesophageal reflux disease.  Remes-Troche JM, García García FD, Rojas-Loureiro G, Rivera-Gutiérrez X, Reyes-Huerta J, Amieva-Balmori M.  Rev Gastroenterol Mex. 2019 May 16. pii: S0375-0906(19)30052-7. doi: 10.1016/j.rgmx.2019.02.006.

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.  Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Cook Bruns N, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar A, Parkhomenko AN, Ryden L, Pogosova N, Dans A, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik T, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne K, Fox KAA, Yusuf S; COMPASS Investigators.  Gastroenterology. 2019 Aug;157(2):403-412.e5. doi: 10.1053/j.gastro.2019.04.041

Continuous Infusion versus Intermittent Dosing with Pantoprazole for Gastric Endoscopic Submucosal Dissection.  Lee BE, Kim GH, Song GA, Seo JH, Jeon HK, Baek DH, Kim DU.  Gut Liver. 2019 Jan 15;13(1):40-47. doi: 10.5009/gnl18222. 

Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer.  Koh JS, Joo MK, Park JJ, Yoo HS, Choi BI, Lee BJ, Chun HJ, Lee SW.  Cell Biosci. 2018 Sep 6;8:50. doi: 10.1186/s13578-018-0248-9.

Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR.  Dabrowski A, Štabuc B, Lazebnik L.  Prz Gastroenterol. 2018;13(1):6-15. doi: 10.5114/pg.2018.74556.

Safety

Anaphylactic reactions due to pantoprazole: case report of two cases.  Gupta PP, Bhandari R, Mishra DR, Agrawal KK, Bhandari R, Jirel S, Malla G.  Int Med Case Rep J. 2018 May 23;11:125-127. doi: 10.2147/IMCRJ.S153099.

Acute generalized exanthematous pustulosis caused by pantoprazole.  Schmitz B, Sorrells T, Glass JS.  Cutis. 2018 May;101(5):E22-E23

Anaphylaxis as a Rare Side Effect of Pantoprazole; a Case Report.  Faridaalaee G, Ahmadian Heris J.  Emerg (Tehran). 2018;6(1):e34

Pantoprazole is a member of the benzimidazole class, acts as a proton pump inhibitor, as a potent inhibitor of gastric acid secretion and is widely used for the treatment of gastroesophageal reflux, dyspepsia and peptic ulcer.

Take only under medical supervision

It also exerts an anti-inflammatory action (1) in gastric and endothelial parietal cells and an antioxidant action through the direct scavenging of reactive oxygen species (2) and has been identified as an oncokinase inhibitor (3).

Pantoprazole offers a lower risk of drug interaction due to lower liver metabolism (4)and this property is useful when used as a potential anticancer therapeutic agent (5). It also did not affect cyclosporin A serum levels in patients who received renal transplantation (6).

This study investigated the effects and mechanism of pantoprazole that led to cell cycle arrest by inducing apoptosis on leukemic cell lines with multi-drug resistance (7).

As a medication, pantoprazole is also inserted in the form of Sodium Pantoprazole or Sodium Pantoprazole Sesquihydrate.

Like all drugs it can cause side effects. Always ask the physician.

Pantoprazole studies

Molecular Formula: C₁₆H₁₅F₂N₃O₄S

Molecular  Weight: 383.4 g/mol

CAS: 102625-70-7  142678-35-1

EC Number: 600-331-6

Synonyms:

• Protonix
• Pantoloc
• Pantozol
• Pantoprozole
• Pantoprazolum
• Astropan
• Somac Control
• Panyocid
• Pantecta Control
• Zosecta
• Pharmakon1600-01505818
• Pantor
• AC-679
• L-Pantoprazole
• Pantoprazol
• Tox21_111477
• 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole
• 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-
• 2-pyridinyl)methyl)sulfinyl)-
• 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-
• benzimidazole
• 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-
• benzimidazole
• 6-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
• 1H-Benzimidazole, 6-(difluoromethoxy)-2-((S)-((3,4-dimethoxy-
• 2-pyridinyl)methyl)sulfinyl)-
• 2-(((3,4-Dimethoxy-2-pyridinyl)methyl)-sulfinyl)-5-methyl-1H-1,3-benzimidazole
• 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methanesulfinyl]-3H-1,3-
• benzodiazole
• 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1H-
• benzo[d]imidazole
• 5-Difluoromethoxy-2-(3,4-dimethoxy-pyridin-2-ylmethanesulfinyl)-1H-
• benzoimidazole
• 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
• 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)-1H-
• benzo[d]imidazole

References_________________________________________________

(1) Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Zeng X, Liu L, Zheng M, Sun H, Xiao J, Lu T, Huang G, Chen P, Zhang J, Zhu F, Li H, Duan Q Oncotarget. 2016 Apr 19; 7(16):22460-73.

(2) Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. Udelnow A, Kreyes A, Ellinger S, Landfester K, Walther P, Klapperstueck T, Wohlrab J, Henne-Bruns D, Knippschild U, Würl P. PLoS One. 2011;6(5):e20143. doi: 10.1371/journal.pone.0020143.

(3) Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Zeng X, Liu L, Zheng M, Sun H, Xiao J, Lu T, Huang G, Chen P, Zhang J, Zhu F, Li H, Duan Q. Oncotarget. 2016 Apr 19;7(16):22460-73. doi: 10.18632/oncotarget.7984.

(4) Pharmacokinetics and pharmacodynamics of the proton pump inhibitors Shin, J.M., Kim, N. Journal of Neurogastroenterology and Motility Volume 19, Issue 1, January 2013,

(5) Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression. Zhang B, Ling T, Zhaxi P, Cao Y, Qian L, Zhao D, Kang W, Zhang W, Wang L, Xu G, Zou X. Cancer Lett. 2019 Jun 28;452:23-30. doi: 10.1016/j.canlet.2019.03.029.

(6) Pantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients. Lorf T, Ramadori G, Ringe B, Schwörer H. Eur J Clin Pharmacol. 2000 Jan;55(10):733-5.

(7) Pantoprazole Induces Apoptosis of Leukemic Cells by Inhibiting Expression of P-Glycoprotein/Multidrug Resistance-Associated Protein-1 Through PI3K/AKT/mTOR Signaling.  Liu M, Tang R, Jiang Y.  Indian J Hematol Blood Transfus. 2017 Dec;33(4):500-508. doi: 10.1007/s12288-017-0808-x.